|
1
|
Leonardi GC, Falzone L, Salemi R, Zanghì
A, Spandidos DA, Mccubrey JA, Candido S and Libra M: Cutaneous
melanoma: From pathogenesis to therapy (Review). Int J Oncol.
52:1071–1080. 2018.PubMed/NCBI
|
|
2
|
Chang AE, Karnell LH and Menck HR: The
national cancer data base report on cutaneous and noncutaneous
melanoma: A summary of 84,836 cases from the past decade. The
American college of surgeons commission on cancer and the American
cancer society. Cancer. 83:1664–1678. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shenenberger DW: Cutaneous malignant
melanoma: A primary care perspective. Am Fam Physician. 85:161–168.
2012.PubMed/NCBI
|
|
4
|
Sampson JH, Carter JH Jr, Friedman AH and
Seigler HF: Demographics, prognosis, and therapy in 702 patients
with brain metastases from malignant melanoma. J Neurosurg.
88:11–20. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ziogas DC, Diamantopoulos P, Benopoulou O,
Anastasopoulou A, Bafaloukos D, Stratigos AJ, Kirkwood JM and Gogas
H: Prognosis and management of BRAF V600E-mutated
pregnancy-associated melanoma. Oncologist. 25:e1209–e1220. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Serrano-Ortega S and Buendía-Eisman A:
Melanoma and pregnancy. Actas Dermosifiliogr. 102:647–649. 2011.(In
Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
7
|
O'Meara AT, Cress R, Xing G, Danielsen B
and Smith LH: Malignant melanoma in pregnancy: A population-based
evaluation. Cancer. 103:1217–1226. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dillman RO, Vandermolen LA, Barth NM and
Bransford KJ: Malignant melanoma and pregnancy ten questions. West
J Med. 164:156–161. 1996.PubMed/NCBI
|
|
9
|
Hepner A, Negrini D, Hase EA, Exman P,
Testa L, Trinconi AF, Filassi JR, Francisco RPV, Zugaib M, O'Connor
TL and Martin MG: Cancer during pregnancy: The oncologist overview.
World J Oncol. 10:28–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Alexander A, Samlowski WE, Grossman D,
Bruggers CS, Harris RM, Zone JJ, Noyes RD, Bowen GM and Leachman
SA: Metastatic melanoma in pregnancy: Risk of transplacental
metastases in the infant. J Clin Oncol. 21:2179–2186. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Davies MA, Saiag P, Robert C, Grob JJ,
Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T,
Mortier L, et al: Dabrafenib plus trametinib in patients with
BRAFV600-mutant melanoma brain metastases (COMBI-MB): A
multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol.
18:863–873. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tawbi HA, Forsyth PA, Hodi FS, Algazi AP,
Hamid O, Lao CD, Moschos SJ, Atkins MB, Lewis K, Postow MA, et al:
Long-term outcomes of patients with active melanoma brain
metastases treated with combination nivolumab plus ipilimumab
(CheckMate 204): Final results of an open-label, multicentre, phase
2 study. Lancet Oncol. 22:1692–1704. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ascierto PA, Mandalà M, Ferrucci PF,
Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello
E, Gogas H, et al: Sequencing of ipilimumab plus nivolumab and
encorafenib plus binimetinib for untreated BRAF-mutated metastatic
melanoma (SECOMBIT): A randomized, three-arm, open-label phase II
trial. J Clin Oncol. 41:212–221. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pagan M, Jinks H and Sewell M: Treatment
of metastatic malignant melanoma during pregnancy with a BRAF
kinase inhibitor. Case Rep Womens Health. 24:e001422019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maleka A, Enblad G, Sjörs G, Lindqvist A
and Ullenhag GJ: Treatment of metastatic malignant melanoma with
vemurafenib during pregnancy. J Clin Oncol. 31:e192–e193. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
de Haan J, van Thienen JV, Casaer M,
Hannivoort RA, Van Calsteren K, van Tuyl M, van Gerwen MM, Debeer
A, Amant F and Painter RC: Severe adverse reaction to vemurafenib
in a pregnant woman with metastatic melanoma. Case Rep Oncol.
11:119–124. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Marcé D, Cornillier H, Denis C,
Jonville-Bera AP and Machet L: Partial response of metastatic
melanoma to BRAF-inhibitor-monotherapy in a pregnant patient with
no fetal toxicity. Melanoma Res. 29:446–447. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Clark WH Jr, From L, Bernardino EA and
Mihm MC: The histogenesis and biologic behavior of primary human
malignant melanomas of the skin. Cancer Res. 29:705–727.
1969.PubMed/NCBI
|
|
19
|
Breslow A: Thickness, cross-sectional
areas and depth of invasion in the prognosis of cutaneous melanoma.
Ann Surg. 172:902–908. 1970. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Keung EZ and Gershenwald JE: The eighth
edition American joint committee on cancer (AJCC) melanoma staging
system: Implications for melanoma treatment and care. Expert Rev
Anticancer Ther. 18:775–784. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Suvarna KS, Layton C and Bancroft JD:
Bancroft's Theory and Practice of Histological Techniques. 8th
edition. Elsevier; Philadelphia, PA: 2018
|
|
22
|
Ramos-Vara JA: Technical aspects of
immunohistochemistry. Vet Pathol. 42:405–426. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ohsie SJ, Sarantopoulos GP, Cochran AJ and
Binder SW: Immunohistochemical characteristics of melanoma. J Cutan
Pathol. 35:433–444. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Apgar V: A proposal for a new method of
evaluation of the newborn infant. Curr Res Anesth Analg.
32:260–267. 1953. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bayley N and Aylward GP: Bayley Scales of
Infant and Toddler Development. 4th edition. Pearson Education,
Inc.; San Antonio, TX: 2019
|
|
26
|
Bayley N: Bayley scales of Infant and
Toddler Development. 3rd edition. Harcourt Assessment; San Antonio,
TX: 2006
|
|
27
|
Nasreddine ZS, Phillips NA, Bédirian V,
Charbonneau S, Whitehead V, Collin I, Cummings JL and Chertkow H:
The montreal cognitive assessment, MoCA: A brief screening tool for
mild cognitive impairment. J Am Geriatr Soc. 53:695–699. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cramer JA and Van Hammée G; N132 Study
Group, : Maintenance of improvement in health-related quality of
life during long-term treatment with levetiracetam. Epilepsy Behav.
4:118–123. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Spitzer RL, Kroenke K, Williams JBW and
Löwe B: A brief measure for assessing generalized anxiety disorder:
The GAD-7. Arch Intern Med. 166:1092–1097. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kroenke K, Spitzer RL and Williams JBW:
The PHQ-9: Validity of a brief depression severity measure. J Gen
Intern Med. 16:606–613. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Global Burden of Disease Cancer
Collaboration, . Fitzmaurice C, Abate D, Abbasi N, Abbastabar H,
Abd-Allah F, Abdel-Rahman O, Abdelalim A, Abdoli A, Abdollahpour I,
et al: Global, regional, and national cancer incidence, mortality,
years of life lost, years lived with disability, and
disability-adjusted life-years for 29 cancer groups, 1990 to 2017:
A systematic analysis for the global burden of disease study. JAMA
Oncol. 5:1749–1768. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ugurel S, Röhmel J, Ascierto PA, Becker
JC, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Livingstone E,
Long GV, et al: Survival of patients with advanced metastatic
melanoma: The impact of MAP kinase pathway inhibition and immune
checkpoint inhibition-update 2019. Eur J Cancer. 130:126–138. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dummer R, Goldinger SM, Turtschi CP,
Eggmann NB, Michielin O, Mitchell L, Veronese L, Hilfiker PR,
Felderer L and Rinderknecht JD: Vemurafenib in patients with
BRAF(V600) mutation-positive melanoma with symptomatic brain
metastases: Final results of an open-label pilot study. Eur J
Cancer. 50:611–621. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Heggarty E, Combarel D, Vialard F,
Rodriguez Y, Grassin-Delyle S, Lamy E, Mir O, Paci A and Berveiller
P: 36 Evaluation of transplacental transfer of cancer therapies in
melanoma via the perfused human placental model. Am J Obstet
Gynecol. 230 (Suppl 1):S28–S29. 2024. View Article : Google Scholar
|
|
35
|
Hassel JC, Livingstone E, Allam JP, Behre
HM, Bojunga J, Klein HH, Landsberg J, Nawroth F, Schüring A, Susok
L, et al: Fertility preservation and management of pregnancy in
melanoma patients requiring systemic therapy. ESMO Open.
6:1002482021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pelczar P, Kosteczko P, Wieczorek E,
Kwieciński M, Kozłowska A and Gil-Kulik P: Melanoma in
pregnancy-diagnosis, treatment, and consequences for fetal
development and the maintenance of pregnancy. Cancers (Basel).
16:21732024. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lorenzi E, Simonelli M, Persico P,
Dipasquale A and Santoro A: Risks of molecular targeted therapies
to fertility and safety during pregnancy: A review of current
knowledge and future needs. Expert Opin Drug Saf. 20:503–521. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tajan M, Paccoud R, Branka S, Edouard T
and Yart A: The RASopathy family: Consequences of germline
activation of the RAS/MAPK pathway. Endocr Rev. 39:676–700. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Grunewald S and Jank A: New systemic
agents in dermatology with respect to fertility, pregnancy, and
lactation. J Dtsch Dermatol Ges. 13:277–290. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Peccatori FA, Azim HA Jr, Orecchia R,
Hoekstra HJ, Pavlidis N, Kesic V and Pentheroudakis G; ESMO
Guidelines Working Group, : Cancer, pregnancy and fertility: ESMO
clinical practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 24 (Suppl 6):vi160–vi170. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Amaral T, Ottaviano M, Arance A, Blank C,
Chiarion-Sileni V, Donia M, Dummer R, Garbe C, Gershenwald JE,
Gogas H, et al: Cutaneous melanoma: ESMO clinical practice
guideline for diagnosis, treatment and follow-up. Ann Oncol.
36:10–30. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Silverstein J, Post AL, Chien AJ, Olin R,
Tsai KK, Ngo Z and Loon KV: Multidisciplinary management of cancer
during pregnancy. JCO Oncol Pract. 16:545–557. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sorouri K, Loren AW, Amant F and Partridge
AH: Patient-centered care in the management of cancer during
pregnancy. Am Soc Clin Oncol Educ Book. 43:e1000372023. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Garzón-Orjuela N, Prieto-Pinto L, Lasalvia
P, Herrera D, Castrillón J, González-Bravo D, Castañeda-Cardona C
and Rosselli D: Efficacy and safety of dabrafenib-trametinib in the
treatment of unresectable advanced/metastatic melanoma with
BRAF-V600 mutation: A systematic review and network meta-analysis.
Dermatol Ther. 33:e131452020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Geng Y, Sun YJ, Song H, Miao QJ, Wang YF,
Qi JL, Xu XL and Sun JF: Construction and identification of an
NLR-associated prognostic signature revealing the heterogeneous
immune response in skin cutaneous melanoma. Clin Cosmet Investig
Dermatol. 16:1623–1639. 2023. View Article : Google Scholar : PubMed/NCBI
|
